Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Amortization of Deferred Charges: 2019-2021

Historic Amortization of Deferred Charges for Viking Therapeutics (VKTX) over the last 3 years, with Dec 2021 value amounting to $296,000.

  • Viking Therapeutics' Amortization of Deferred Charges rose 6.94% to $77,000 in Q1 2022 from the same period last year, while for Mar 2022 it was $301,000, marking a year-over-year increase of 7.12%. This contributed to the annual value of $296,000 for FY2021, which is 6.86% up from last year.
  • Per Viking Therapeutics' latest filing, its Amortization of Deferred Charges stood at $296,000 for FY2021, which was up 6.86% from $277,000 recorded in FY2020.
  • Viking Therapeutics' Amortization of Deferred Charges' 5-year high stood at $296,000 during FY2021, with a 5-year trough of $260,000 in FY2019.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $277,000 (2020), whereas its average is $277,667.
  • Data for Viking Therapeutics' Amortization of Deferred Charges shows a peak YoY grew of 6.86% (in 2021) over the last 5 years.
  • Viking Therapeutics' Amortization of Deferred Charges (Yearly) stood at $260,000 in 2019, then grew by 6.54% to $277,000 in 2020, then grew by 6.86% to $296,000 in 2021.